Waugh, Norman, Scotland, Graham, McNamee, Paul, Gillett, M. (Michael), Brennan, Alan, Goyder, Elizabeth, Williams, R. (Rhys) and John, A.. (2007) Screening for type 2 diabetes : literature review and economic modelling. Health Technology Assessment, Vol.11 (No.17). ISSN 1366-5278

Preview	Text WRAP_Waugh_screeningTAR.pdf - Published Version Download (653Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh1_Coversheet_FinalVersion.pdf Download (168Kb) | Preview

Abstract

Objectives: To reconsider the aims of screening for undiagnosed diabetes, and whether screening should be for other abnormalities of glucose metabolism such as impaired glucose tolerance (IGT), or the ‘metabolic syndrome’. Also to update the previous review for the National Screening Committee (NSC) on screening for diabetes, including reviewing choice of screening test; to consider what measures would be taken if IGT and impaired fasting glucose (IFG) were identified by screening, and in particular to examine evidence on treatment to prevent progression to diabetes in these groups; to examine the cost-effectiveness of screening; and to consider groups at higher risk at which screening might be targeted. Data sources: Electronic databases were searched up to the end of June 2005. Review methods: Literature searches and review concentrated on evidence published since the last review of screening, both reviews and primary studies. The review of economic studies included only those models that covered screening. The new modelling extended an existing diabetes treatment model by developing a screening module. The NSC has a set of criteria, which it applies to new screening proposals. These criteria cover the condition, the screening test or tests, treatment and the screening programme. Screening for diabetes was considered using these criteria. Results: Detection of lesser degrees of glucose intolerance such as IGT is worthwhile, partly because the risk of cardiovascular disease (CVD) can be reduced by treatment aimed at reducing cholesterol level and blood pressure, and partly because some diabetes can be prevented. Several trials have shown that both lifestyle measures and pharmacological treatment can reduce the proportion of people with IGT who would otherwise develop diabetes. Screening could be two-stage, starting with the selection of people at higher risk. The second-stage choice of test for blood glucose remains a problem, as in the last review for NSC. The best test is the oral glucose tolerance test (OGTT), but it is the most expensive, is inconvenient and has weak reproducibility. Fasting plasma glucose would miss people with IGT. Glycatedhaemoglobin does not require fasting, and may be the best compromise. It may be that more people would be tested and diagnosed if the more convenient test was used, rather than the OGTT. Five economic studies assessed the costs and short-term outcomes of using different screening tests. None examined the long-term impact of different proportions of false negatives. All considered the costs that would be incurred and the numbers identified by different tests, or different cut-offs. Results differed depending on different assumptions. They did not give a clear guide as to which test would be the best in any UK screening programme, but all recognised that the choice of cut-off would be a compromise between sensitivity and specificity; there is no perfect test. The modelling exercise concluded that screening for diabetes appears to be cost-effective for the 40–70-year age band, more so for the older age bands, but even in the 40–49-year age group, the incremental cost-effectiveness ratio for screening versus no screening is only £10,216 per quality-adjusted life-year. Screening is more cost-effective for people in the hypertensive and obese subgroups and the costs of screening are offset in many groups by lower future treatment costs. The cost-effectiveness of screening is determined as much by, if not more than, assumptions about the degree of control of blood glucose and future treatment protocols than by assumptions relating to the screening programme. The very low cost now of statins is also an important factor. Although the prevalence of diabetes increases with age, the relative risk of CVD falls, reducing the benefits of screening. Screening for diabetes meets most of the NSC criteria, but probably fails on three: criterion 12, on optimisation of existing management of the condition; criterion 13, which requires that there should be evidence from high-quality randomised controlled trials (RCTs) showing that a screening programme would reduce mortality or morbidity; and criterion 18, that there should be adequate staffing and facilities for all aspects of the programme. It is uncertain whether criterion 19, that all other options, including prevention, should have been considered, is met. The issue here is whether all methods of improving lifestyles in order to reduce obesity and increase exercise have been sufficiently tried. The rise in overweight and obesity suggests that health promotion interventions have not so far been effective. Conclusions: The case for screening for undiagnosed diabetes is probably somewhat stronger than it was at the last review, because of the greater options for reduction of CVD, principally through the use of statins, and because of the rising prevalence of obesity and hence type 2 diabetes. However, there is also a good case for screening for IGT, with the aim of preventing some future diabetes and reducing CVD. Further research is needed into the duration of undiagnosed diabetes, and whether the rise in blood glucose levels is linear throughout or whether there may be a slower initial phase followed by an acceleration around the time of clinical diagnosis. This has implications for the interval after which screening would be repeated. Further research is also needed into the natural history of IGT, and in particular what determines progression to diabetes. An RCT of the type required by NSC criterion 13 is under way but will not report for about 7 years.

Item Type:	Journal Article
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Medical screening, Non-insulin-dependent diabetes -- Diagnosis, Hyperglycemia -- Diagnosis, Hyperglycemia -- Treatment
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	2007
Volume:	Vol.11
Number:	No.17
Number of Pages:	144
Status:	Peer Reviewed
Publication Status:	Published
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001;322:986–8. 2. Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. Health Technol Assess 2002;6:(11). 3. Yorkshire and Humber Public Health Observatory. PBS diabetes population prevalence model. 2005. URL: http://www.yhpho.org.uk/viewResource.aspx?id=7. Accessed 26 December 2006. 4. Ritz E. Hypertension and nephropathy in type II diabetes. Proc R Coll Physicians Edinb 1996; 26:374–83. 5. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, et al. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 2003; 34:418–21. 6. Waugh NR. Amputations in diabetic patients – a review of rates, relative risks and resource use. Community Med 1988;10:279–88. 7. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabetic Med 1999;16:2–13. 8. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. 9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65. 10. Goyder E, Irwig L. Screening for diabetes: what are we really doing? BMJ 1998;317:1644–6. 11. Jarrett RJ. Screening for type II diabetes mellitus. Journal Med Screen 2000;7:2–3. 12. Keen H. The Bedford survey: a critique of methods and findings. Proc R Soc Med 1964; 57:196–202. 13. Welborn TA, Curnow DH, Wearne JT, Cullen KJ, McCall MG, Stenhouse NS. Diabetes detected by blood-sugar measurement after a glucose load: report from the Busselton survey, 1966. Med J Aust 1968;2:778–83. 14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998;15:539–53. 15. World Health Organization. Diabetes mellitus: Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO; 1985. 16. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–73. 17. Gavin II, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97. 18. Keen H. Criteria and classification of diabetes mellitus. In Mann JI, Pyorala K, Teuscher A, editors. Diabetes in epidemiological perspective. Edinburgh: Churchill Livingstone; 1983. pp. 167–82. 19. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979; 28:1039–57. 20. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser 1980;646:1–80. 21. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58. 22. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617–21. 23. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–40. 24. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999;48:2197–203. 25. Festa A, D’Agostino R, Jr., Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004;53:1549–55. 26. Davies MJ, Gray IP. Impaired glucose tolerance. BMJ 1996;312:264–5. 27. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236–9. 28. Charles MA, Balkau B, Vauzelle-Kervroedan F, Thibult N, Eschwege E. Revision of diagnostic criteria for diabetes. Lancet 1996;348:1657–8. 29. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356–61. 30. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985;701:38–52. 31. Haffner SM. Update on diabetes and the metabolic syndrome. Adv Stud Med 2003;3:277–85. 32. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K, et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 2004; 47:1245–56. 33. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920–4. 34. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322:15–18. 35. Piche ME, Lemieux S, Perusse L, Weisnagel SJ. High normal 2-hour plasma glucose is associated with insulin sensitivity and secretion that may predispose to type 2 diabetes. Diabetologia 2005; 48:732–40. 36. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005;28:1981–7. 37. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7. 38. Balkau B, Hillier T, Vierron E, D’Hour A, Lepinay P, Royer B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2005;48:801–2. 39. Piche ME, Despres JP, Pascot A, Nadeau A, Tremblay A, Weisnagel SJ, et al. Predictors of the development of impaired fasting glucose versus impaired glucose tolerance are partly different in men: a 6-year follow-up study. Diabetologia 2004; 47:590–2. 40. Reynolds K, Muntner P, Fonseca V. Metabolic syndrome: underrated or underdiagnosed? Diabetes Care 2005;28:1831–2. 41. NCEP. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97. 42. Jarrett RJ, Fitzgerald AP. Non-insulin-dependent diabetes mellitus, glucose intolerance, blood pressure, hypertension, and antihypertensive drugs. Diabetic Med 1994;11:646–9. 43. Scheen AJ. Renin–angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A metaanalysis of randomised clinical trials. Diabetes Metab 2004;30:487–96. 44. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261–6. 45. Scuteri A, Najjar SS, Morrell CH, Lakatta EG. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005;28:882–7. 46. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769–78. 47. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676–81. 48. Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005;48:649–56. 49. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor’s clothes fit? Diabetes Care 2004;27: 1011–12. 50. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684–99. 51. Perry IJ, Villegas R, Salim A, Flynn A. Clustering of protective factors for glucose intolerance and insulin resistance: a cross-sectional study. Diabet Med 2005;22:1091–7. 52. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415. 53. Heidemann C, Hoffmann K, Spranger J, Klipstein-Grobusch K, Mohlig M, Pfeiffer AF, et al. A dietary pattern protective against type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam Study cohort. Diabetologia 2005;48:1126–34. 54. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815–19. 55. Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2001; 119:547–53. 56. Jarrett RJ. Duration of non-insulin-dependent diabetes and development of retinopathy: analysis of possible risk factors. Diabet Med 1986;3:261–3. 57. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabetic Med 1996;13:337–40. 58. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK prospective diabetes study 61. Diabetes Care 2002;25:1410–17. 59. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes: a matched cohort study. Diabetes Care 2005;28:47–52. 60. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96:281–8. 61. Jarrett RJ. Do we need IGT? Diabetic Med 1987; 4:544–5. 62. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701–10. 63. Department of Health. Health Survey for England 2003: latest trends: Table 6: body mass index (BMI), by survey year, age and sex. 2005. URL: http://www.dh.gov.uk/assetRoot/04/09/89/15/ 04098915.xls. Accessed 26 December 2006. 64. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563–76. 65. Oldridge NB, Stump TE, Nothwehr FK, Clark DO. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol 2001;54:928–34. 66. Dunstan DW, Zimmet PZ, Welborn TA, de Court, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829–34. 67. Glatthaar C, Welborn TA, Stenhouse NS, Garcia-Webb P. Diabetes and impaired glucose tolerance. A prevalence estimate based on the Busselton 1981 survey. Med J Aust 1985; 143:436–40. 68. Guest CS, O’Dea K, Hopper JL, Nankervis AJ, Larkins RG. The prevalence of glucose intolerance in aborigines and Europids of south-eastern Australia. Diabetes Res Clin Pract 1992;15:227–35. 69. Leiter LA, Barr A, Belanger A, Lubin S, Ross SA, Tildesley HD, et al. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 2001;24:1038–43. 70. Prevalence of diabetes and impaired fasting glucose in adults – United States, 1999–2000. MMWR Morb Mortal Wkly Rep 2003;52:833–7. 71. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003;21:543–64. 72. Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD. Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 2000; 23:770–4. 73. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001; 44:2140–55. 74. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13–S17. 75. Audit Commission. Testing times: a review of diabetes services in England and Wales. 2000. URL: http://www.audit-commission.gov.uk/Products/ NATIONAL-REPORT/EB2CA6BA-C5E5-4B8FA984- 898D19E8C603/nrdiabet.pdf. Accessed 27 December 2006. 76. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000;23:1563–80. 77. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685–96. 78. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335–41. 79. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16. 80. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;138:215–29. 81. Royle PL, Bain L, Waugh NR. Sources of evidence for systematic reviews of interventions in diabetes. Diabet Med 2005;22:1386–93. 82. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. 2003. URL: http://www.ahrq.gov/clinic/3rduspstf/diabscr/ diabrev.pdf. Accessed 27 December 2006. 83. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755–62. 84. Ravid M, Rachmani R. Treatment of diabetic nephropathy: anti-hypertensive treatment. In Boner G, Cooper ME, editors. Management of diabetic nephropathy. London: Martin Dunitz; 2003. pp. 105–28. 85. ALLHAT-LLT. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007. 86. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events: Technology Appraisal 94. 2006. www.nice.org.uk. Accessed 28 December 2006. 87. Williamson DF, Vinicor F, Bowman BA, Centers for Disease Control and Primary Prevention. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: Implications for health policy. Ann Intern Med 2004;140:951–7. 88. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–44. 89. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50. 90. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403. 91. Harris MI, Modan M. Screening for NIDDM. Why is there no national program? Diabetes Care 1994; 17:440–4. 92. Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Rese Rev 2000;16:230–6. 93. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23 Suppl 1:S4–19. 94. Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A. Screening for type 2 diabetes – should it be now? Diabetic Med 2003;20:175–81. 95. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the costeffectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24 Suppl 3:S6–11. 96. American Diabetes Association. Position statement: early identification of people with type 2 diabetes. 2002. URL: http://www.diabetes.org.uk/About_us/ Our_Views/Position_statements/Early_ identification_of_people_with_type_2_diabetes/. Accessed 26 December 2006. 97. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28 Suppl 1:S4–36. 98. Hardman AE, Stensel DJ. Physical activity and health. London: Routledge; 2003. 99. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992; 268:63–7. 100. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790–7. 101. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891–8. 102. Tan HH, McAlpine RR, James P, Thompson P, McMurdo MET, Morris AD, et al. Diagnosis of type 2 diabetes at an older age: Effect on mortality in men and women. Diabetes Care 2004;27:2797–9. 103. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997; 127:788–95. 104. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001;24:1377–83. 105. Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, et al. Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999; 22:213–19. 106. Adriaanse MC, Snoek FJ, Dekker JM, Van der Ploeg HM, Heine RJ. Screening for type 2 diabetes: an exploration of subjects’ perceptions regarding diagnosis and procedure. Diabetic Med 2002;19:406–11. 107. Herman WH, Smith PJ, Thompson TJ, Engelgau MM, Aubert RE. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 1995; 18:382–7. 108. Burden ML, Burden AC. The American Diabetes Association screening questionnaire for diabetes. Is it worthwhile in the UK? Diabetes Care 1994; 17:97. 109. Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005; 28:1187–94. 110. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000;16:164–71. 111. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 2002; 25:1784–9. 112. Greaves CJ, Stead JW, Hattersley AT, Ewings P, Brown P, Evans PH. A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia in primary care. Fam Pract 2004;21:57–62. 113. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013–18. 114. Davies M, Alban-Davies H, Cook C, Day J. Self testing for diabetes mellitus. BMJ 1991;303:696–8. 115. Qiao Q, Keinanen-Kiukaanniemi S, Rajala U, Uusimaki A, Kivela SL. Random capillary whole blood glucose test as a screening test for diabetes mellitus in a middle-aged population. Scand J Clin Lab Invest 1995;55:3–8. 116. NGSP. National Glycohemoglobin Standardization Program. 2006. URL: www.ngsp.org. Accessed 28 December 2006. 117. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26 Suppl 1:S5–20. 118. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413–20. 119. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med 2004;141:475–6. 120. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population. Diabetes Care 2000;23:187–91. 121. Ellison TL, Elliott R, Moyes SA. HbA1c screening for undiagnosed diabetes in New Zealand. Diabetes Metab Res Rev 2005;21:65–70. 122. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308:1323–8. 123. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996;276:1246–52. 124. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values. Arch Intern Med 2004; 164:1627–32. 125. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabetic Med 2004;21:657–65. 126. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881–5. 127. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J Med Screen 2002;9:187–90. 128. Hanson RL, Nelson RG, McCance DR, Beart JA, Charles MA, Pettitt DJ, et al. Comparison of screening tests for non-insulin-dependent diabetes mellitus. Arch Intern Med 1993;153:2133–40. 129. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83. 130. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8:(36). 131. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. JAMA 1998;280:1757–63. 132. Chen TH, Yen MF, Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;54:S37–42. 133. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689–99. 134. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–44. 135. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725–34. 136. Goyder EC, Irwig LM. Screening for type 2 diabetes mellitus: a decision analytic approach. Diabetic Med 2000;17:469–77. 137. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD, et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 1995;12:30–5. 138. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642–52. 139. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. 140. UKPDS Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877–90. 141. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136–45. 142. Welborn TA, Glatthaar C, Whittall D, Bennett S. An estimate of diabetes prevalence from a national population sample: a male excess. Med J Aust 1989;150:78–81. 143. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and noninsulin- dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990; 131:443–53. 144. Davies M, Day J. Screening for non-insulindependent diabetes mellitus (NIDDM): how often should it be performed? J Med Screen 1994; 1:78–81. 145. Andersson DK, Svardsudd K, Tibblin G. Prevalence and incidence of diabetes in a Swedish community 1972–1987. Diabetic Med 1991; 8:428–34. 146. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–5. 147. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–20. 148. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project – a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899–905. 149. Fuller J, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Review. Chichester: Wiley; 1997. Issue 4, CD 002188. 150. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886–92. 151. UK Prospective Diabetes Study. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13. 152. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a populationbased cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817–24. 153. Humphrey LL, Palumbo PJ, Butters MA, Hallett JW Jr, Chu CP, O’Fallon WM, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 1994;154:885–92. 154. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, editors. Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. 1995. pp. 409–28. 155. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995;18:182–7. 156. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244–9. 157. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8. 158. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59. 159. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987;77:1417–26. 160. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277:535–42. 161. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–34. 162. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086–97. 163. Dasbach EJ, Fryback DJ, Thornbury JR. Health utility preference differences [abstract]. Med Decis Making 1992;12:4. 164. Klein R, Klein BE, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 1993;16:1325–30. 165. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA 1995;273:712–20. 166. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of timetradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161–5. 167. Wolf PA, D’Agostino RB, O’Neal MA, Sytkowski P, Kase CS, Belanger AJ, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992;23:1551–5. 168. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston, MA: Harvard School of Public Health; 1996. 169. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–94. 170. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26:2518–23. 171. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–32. 172. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304–21. 173. Caro JJ, Getsios D, Caro I, Klittich WS, O’Brien JA. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabetic Med 2004;21:1229–36. 174. Segal L, Dalton AC, Richardson J. Costeffectiveness of the primary prevention of noninsulin dependent diabetes mellitus. Health Promot Internation 1998;13:197–209. 175. McEwan P, Bergenheim K, Peters JR, Williams R, Currie CJ. Delaying the onset of type 2 diabetes may have a substantial impact on macrovascular and microvascular events and patient costs. Poster presented at the 65th Annual Scientific Session of the American Diabetes Association, 10–14 June 2005. 176. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 yr. Diabetes 1987; 36:523–34. 177. Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476–81. 178. Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O’Brien JA, Shomphe LA, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 2000;22:116–27. 179. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337–40. 180. Qureshi AI, Giles WH, Croft JB. Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke 1998; 29:1329–32. 181. Barzilay JI, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS, et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care 2001; 24:1233–9. 182. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116:297–303. 183. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32. 184. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101:671–9. 185. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81. 186. Balkau B, Eschwege E, Papoz L, Richard JL, Claude JR, Warnet JM, et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 1993; 307:295–9. 187. Simons LA, McCallum J, Friedlander Y, Simons J. Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. Aust N Z J Med 1996;26:66–74. 188. Lee IM, Manson JE, Hennekens CH, Paffenbarger RS Jr. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993;270:2823–8. 189. Rissanen A, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Maatela J. Risk of disability and mortality due to overweight in a Finnish population. BMJ 1990;301:835–7. 190. Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity. A reassessment. JAMA 1987;257:353–8. 191. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;24:447–53. 192. Dong F, Orians C, Manninen D. Economic evaluation of approaches to preventing diabetic endstage renal disease. Prepared for the Centers for Disease Control and Prevention. Seattle, WA: Battelle- Centers for Public Health Research and Evaluation; 1997. 193. O’Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the US. Diabetes Care 1998;21:1122–8. 194. O’Brien JA, Caro I, Getsios D, Caro JJ. Diabetes in Canada: direct medical costs of major macrovascular complications. Value Health 2001; 4:258–65. 195. Jonsson B, Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45:S5–12. 196. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care 2000;23:1654–9. 197. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300–4. 198. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–81. 199. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000; 23:390–404. 200. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross sectional population study. BMJ 2001;323:548–51. 201. Icks A, Haastert B, Gandjour A, John J, Lowel H, Holle R, et al. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000. Diabetes Care 2004; 27:2120–8. 202. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the US. population 45–74 years of age. Diabetes Care 2005; 28:307–11. 203. Shirasaya K, Miyakawa M, Yoshida K, Takahashi E, Shimada N, Kondo T. Economic evaluation of alternative indicators for screening for diabetes mellitus. Prev Med 1999;29:79–86. 204. Zhang P, Engelgau MM, Valdez R, Benjamin SM, Cadwell B, Narayan KM. Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care 2003; 26:2536–42. 205. Zhang P, Engelgau MM, Valdez R, Cadwell B, Benjamin SM, Narayan KM. Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care 2005;28:1321–5. 206. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003;46:182–9. 207. Bureau of the Census. Population projections of the United States by age, race and Hipanic origin: 1995 to 2050. Current Population Reports. Washington, DC: US Government Printing Office; 1996. 208. National Center for Health Statistics. Third national health and nutrition examination survey, 1988–1994, reference manual and reports. Manual for medical technicians and laboratory procedures used for NHANES III. Hyattsville, MD: Centers for Disease Control and Prevention; 1996. 209. Diabetes in the UK. 2004. URL: http://www.diabetes.org.uk/Professionals/ Information_resources/Reports/Diabetes_in_the_ UK_2004/. Accessed 26 December 2006. 210. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the US population according to the 1997 American Diabetes Association and 1980–1985 World Health Organization diagnostic criteria. Diabetes Care 1997;20:1859–62. 211. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD, Early Diabetes Intervention Program. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnositc levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001;24:465–71. 212. Simmons D. Parity, ethnic group and the prevalence of type 2 diabetes: the Coventry Diabetes Study. Diabet Med 1992;9:706–9. 213. Hofer TP, Vijan S, Hayward RA. Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 2000;16:822–33. 214. O’Connor PJ, Rush WA, Engelgau M, Gregg EW, Stiffman MN. What a difference a year makes: changes in blood pressure, HbA1c, LDL, and weight within one year of a new diagnosis of diabetes. Presented at the Centers for Disease Control. Diabetes Translation Conference, New Orleans, LA, 2000. 215. Gatling W, Guzder RN, Turnbull JC, Budd S, Mullee MA. The Poole Diabetes Study: how many cases of type 2 diabetes are diagnosed each year during normal health care in a defined community? Diabetes Res Clin Pract 2001;53:107–12. 216. Topp B, Promislow K, deVries G, Miura RM, Finegood DT. A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol 2000;206:605–19. 217. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. The Natural History of Type 2 Diabetes (Chart), in Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: oral agents, insulin, and management of complications. In DeGroot LJ, Jameson JL, editors. Endocrinology, Chapter 58. Philadelphia, PA: Saunders; 2001. 218. Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK. Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001;24:1167–74. 219. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421–31. 220. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). US National Institutes of Health (NIH) News. 2005. URL: http://www.nih.gov/news/pr/jun2005/niddk- 12a.htm. Accessed 26 December 2006. 221. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–12. 222. ScHARR. Health Economics and Decision Sciences website – Discussion Papers. 2005. URL: http://www.shef.ac.uk/scharr/sections/heds/ discussion.html. Accessed 26 December 2006. 223. Speight J. Assessing the impact of diabetes screening on quality of life or quality of health?: semantics are important. Diabetes Care 2002; 25:1893–4. 224. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care 2002;25:1022–6. 225. Forouhi NG, Merrick D, Goyder E, Ferguson BA, Abbas J, Lachowycz K, et al. Diabetes prevalence in England, 2001 – estimates from an epidemiological model. Diabetic Med 2006; 23:189–97. 226. PBS prevalence model documentation. 2005. URL: http://www.yhpho.org.uk/viewResource.aspx?id=7. Accessed 26 December 2006. 227. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53. 228. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993; 16:157–77. 229. The National Clinical Audit Support Programme (NCASP). National Diabetes Audit. 2006. URL: http://www.icservices.nhs.uk/ncasp/pages/audit_ topics/diabetes/default-new.asp. Accessed 26 December 2006. 230. Conference Report on ADA: Diabetic Retinopathy Detected in Pre-Diabetes Patients. 2005. URL: http://www.medpagetoday.com/Endocrinology/ 2005ADAMeeting/tb/1185. Accessed 26 December 2006. 231. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–63. 232. Tayside Diabetes Network. The Tayside diabetes handbook – screening and management of retinopathy. 2005. URL: http://www.diabetes-healthnet.ac.uk/ handbook/eyecomp.htm. Accessed 26 December 2006. 233. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894–9. 234. Prescription Pricing Authority. NHS Drug Tariff. 2005. URL: http://www.ppa.org.uk/edt/July_2005/ mindex.htm. Accessed 26 December 2006. 235. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968–83. 236. O’Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models. 2005. URL: http://www.tonyohagan.co.uk/academic/abs/ MCPSA.html. Accessed 26 December 2006. 237. UCL Department of Epidemiology and Public Health. Whitehall II Study. 2006. URL: http://www.ucl.ac.uk/whitehallII/publications/ index.htm. Accessed 26 December 2006. 238. The Oxford Centre for Diabetes EaMDTU. The UK Prospective Diabetes Study. 2006. URL: http://www.dtu.ox.ac.uk/index.php?maindoc=/ ukpds/. Accessed 27 December 2006. 239. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997;315:524–8. 240. Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care 2004;27:2752–4. 241. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004;27:727–33. 242. Selective review of the literature on the relationship between BMI and type 2 diabetes. [See Appendix 2 of PBS Diabetes Population Prevalence Model – Phase 2 Briefing Document]. 2005. URL: http://www.york.ac.uk/yhpho/documents/pbsdpm/ pbs%20phase%202/PBS%20Briefing%20Document %20-%20Phase2.pdf. Accessed 26 December 2006. 243. UK Prospective Diabetes Study. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995; 44:1249–58. 244. Wilson JM, Junger G. Principles and practice of screening for disease. Public Health Paper Number 34. Geneva: WHO; 1968. 245. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ (Clin Res Ed) 1981; 282:1847–51. 246. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a metaanalysis of controlled clinical trials. JAMA 2001; 286:1218–27. 247. Williams R, Herman W, Kinmonth AL, Wareham N, editors. The evidence base for diabetes care. Chichester: Wiley; 2002. 248. Hamman RF. Prevention of type 2 diabetes. The evidence base for diabetes care. Chichester: Wiley; 2002. pp. 75–176. 249. Keen H, Jarrett RJ, Fuller JH. Tolbutamide and arterial disease in borderline diabetics. Exerpta Med Int Congr Ser 1968;312:588–602. 250. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia 1982; 22:73–8. 251. Paasikivi J. Long-term tolbutamide treatment after myocardial infarction. A clinical and biochemical study of 178 patients without overt diabetes. Acta Med Scand Suppl 1970;507:1–82. 252. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41–9. 253. Engelgau M, Narayan KM. The evidence to screen for type 2 diabetes mellitus. In Williams R, Herman W, Kinmonth AL, Wareham N, editors. The evidence base for diabetes care. Chichester: Wiley; 2002. pp. 191–233. 254. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. The prevention or delay of type 2 diabetes. Diabetes Care 2003; 26(Suppl 1):S62–9. 255. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27(Suppl 1): S11–14. 256. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabetic Med 2004;21:403–14. 257. Williams R, Rapport F, Elwyn G, Lloyd B, Rance J, Belcher S. The prevention of type 2 diabetes: general practitioner and practice nurse opinions. Br J Gen Pract 2004;54:531–5. 258. Wylie G, Hungin AP, Neely J. Impaired glucose tolerance: qualitative and quantitative study of general practitioners’ knowledge and perceptions. BMJ 2002;324:1190. 259. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebocontrolled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217–31. 260. Sjostrom L, Torgerson JS, Hauptman J, Boldrin M. XENDOS (XENical in the prevention of Diabetes in Obese Subjects): a landmark study. Presented at the 9th International Congress on Obesity, São Paulo, 2002. 261. Gerstein HC. Emerging pharmacologic approaches to diabetes prevention. Presented at the 15th National Congress, Associazione Medici Diabetologi, Genoa, 18–21 May 2005. 262. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1–9. 263. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. The diabetes prevention program and its global implications. J Am Soc Nephrol 2003;14:S103–7. 264. Herman W, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003;26:36–47. 265. Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumaki M, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol 2003;14:S108–13. 266. Mensink M, Corpeleijn E, Feskens EJ, Kruijshoop M, Saris WH, de Bruin TW, et al. Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003;61:49–58. 267. Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003;26:290–6. 268. McEwan P, Williams R, Bergenheim K, Peters JR, Currie CJ. Economic benefits of delaying the onset of type 2 diabetes. In preparation. 2005.
URI:	http://wrap.warwick.ac.uk/id/eprint/52119

Request changes to a record

Actions (login required)

View Item